Abstract
Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Keywords: Angiogenesis, carcinogenesis, focal adhesion kinase, targeted therapeutics, tyrosine kinase, Cancer, metastatic disease, cytotoxic chemotherapy, Tyrosine Kinase inhibitors, chronic myelogenous leukemia, RTK induces, CDK, Epidermal growth factor receptor, Vascular endothelial growth factor, flavopiridol
Anti-Cancer Agents in Medicinal Chemistry
Title: Evolving Therapies and FAK Inhibitors for the Treatment of Cancer
Volume: 10 Issue: 10
Author(s): Kelli Bullard Dunn, Melissa Heffler and Vita M. Golubovskaya
Affiliation:
Keywords: Angiogenesis, carcinogenesis, focal adhesion kinase, targeted therapeutics, tyrosine kinase, Cancer, metastatic disease, cytotoxic chemotherapy, Tyrosine Kinase inhibitors, chronic myelogenous leukemia, RTK induces, CDK, Epidermal growth factor receptor, Vascular endothelial growth factor, flavopiridol
Abstract: Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Export Options
About this article
Cite this article as:
Bullard Dunn Kelli, Heffler Melissa and M. Golubovskaya Vita, Evolving Therapies and FAK Inhibitors for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728657
DOI https://dx.doi.org/10.2174/187152010794728657 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Benzophenone Sulfonamide Derivatives as Interacting Partners and Inhibitors of Human P-glycoprotein
Anti-Cancer Agents in Medicinal Chemistry Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics EDITORIAL (Hot Topic: “Signal Transduction and Response to Anti-Cancer Therapy”)
Current Signal Transduction Therapy Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives
Current Drug Therapy Overview and Developments Regarding Functional Foods and Beverages
Current Nutrition & Food Science MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Tubulin/Microtubule System as an Anti-Cancer Drug Target (Guest Editor: A/Prof. Maria Kavallaris Ph.D.) ]
Current Cancer Drug Targets Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews Molecular Pathways and Related Target Therapies in Liver Carcinoma
Current Pharmaceutical Design Counteraction of Skin Inflammation and Aging or Cancer by Polyphenols and Flavonoids from Polypodium leucotomos and Xanthohumol
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Current Drug Targets Antibodies in Diagnostic Applications
Current Pharmaceutical Biotechnology Cellular Responses to 24R,25-dihydroxyvitamin D3 in Bone and Cartilage
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
Reviews on Recent Clinical Trials